Clinical Trials in Baltimore

Showing 4581-4600 of 23,476 trials

Evolocumab in Patients With Acute MI

NCT04082442

Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators' pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation. The addition of the PCSK9 antibody evolocumab, currently approved to lower LDL-C in certain patient populations, to current medical therapies would appear to be of particular benefit in patients with an ACS by markedly reducing LDL-C, stabilizing vulnerable plaque, and limiting inflammation-associated myocardial cell loss and resultant dysfunction.

Acute Coronary Syndrome

Johns Hopkins University100 participantsStarted Sep 2019

Baltimore, Maryland, United States

TERMINATEDPhase 1< 1 mile

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04543188

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.

Malignant MelanomaCarcinoma, Non-Small-Cell LungBrain Neoplasms, Primary+2 more

Pfizer65 participantsStarted Jan 2021

Duarte, California, United States • San Francisco, California, United States • Orlando, Florida, United States +42 more locations

Evolocumab in Patients With Acute MI

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Find Trials by Condition in Baltimore

Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

The Myelin Disorders Biorepository Project

Expanded Access Protocol Using HBOC-201

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Minima Stent System Post- Approval Study (PAS)

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Non-Operative Management and Early Response Assessment in Rectal Cancer

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors